Aim to sustain 25% topline growth in FY17: Thyrocare

Thyrocare Technologies' imaging business will become the company's future growth driver, says Chairman, CEO & MD A Velumani. The diagnostic company is betting big on the radiology vertical which requires huge capex, but capable of bringing in good business.

Speaking to CNBC-TV18, Velumani says Thyrocare is likely to sustain 25 percent growth in top line in FY17.

The company was not much impacted by demonetisation as was expected, Velumani said. 

He believes growth in the pathology business is likely to be affected on lack of entry barriers. Dollar appreciation also a threat as 90 percent of the products are imported.